Cargando…

Effects of lamivudine on serum albumin levels correlate with pretreatment HBV-DNA levels in cirrhotic patients

BACKGROUND: Lamivudine treatment has been recently demonstrated to increase the serum albumin levels in cirrhotic patients with hepatitis B virus (HBV) infection, but the precise mechanism remains unclear. We hypothesized that the improvement of hypoalbuminemia by lamivudine may be attributable to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nakamuta, Makoto, Kotoh, Kazuhiro, Enjoji, Munechika, Kajiwara, Eiji, Shimono, Junya, Masumoto, Akihide, Maruyama, Toshihiro, Furusyo, Norihiro, Nomura, Hideyuki, Sakai, Hironori, Takahashi, Kazuhiro, Azuma, Koichi, Shimoda, Shinji, Tanabe, Yuichi, Hayashi, Jun
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2007
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1884174/ https://www.ncbi.nlm.nih.gov/pubmed/17470300 http://dx.doi.org/10.1186/1476-5926-6-3

Ejemplares similares

Metabolic Disorders and Steatosis in Patients with Chronic Hepatitis C: Metabolic Strategies for Antiviral Treatments
por: Enjoji, Munechika, et al.
Publicado: (2012)

A new parameter using serum lactate dehydrogenase and alanine aminotransferase level is useful for predicting the prognosis of patients at an early stage of acute liver injury: A retrospective study
por: Kotoh, Kazuhiro, et al.
Publicado: (2008)

Nutrition Therapy for Liver Diseases Based on the Status of Nutritional Intake
por: Yasutake, Kenichiro, et al.
Publicado: (2012)

Comparison of tissue pressure and ablation time between the LeVeen and cool-tip needle methods
por: Nakamuta, Makoto, et al.
Publicado: (2006)

NIM811, a nonimmunosuppressive cyclosporine analogue, suppresses collagen production and enhances collagenase activity in hepatic stellate cells
por: Kohjima, Motoyuki, et al.
Publicado: (2007)

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease
por: Enjoji, Munechika, et al.
Publicado: (2010)

A high prevalence of extreme hyperferritinemia in acute hepatitis patients
por: Kotoh, Kazuhiro, et al.
Publicado: (2009)

Intrahepatic microcirculatory disorder, parenchymal hypoxia and NOX4 upregulation result in zonal differences in hepatocyte apoptosis following lipopolysaccharide- and D-galactosamine-induced acute liver failure in rats
por: TANAKA, MASATAKE, et al.
Publicado: (2014)

Nutrition and Nonalcoholic Fatty Liver Disease: The Significance of Cholesterol
por: Enjoji, Munechika, et al.
Publicado: (2012)

Transforming Growth Factor‐α Induces the Differentiation of Sarcomatoid Cholangiocarcinoma Cells
por: Enjoji, Munechika, et al.
Publicado: (2000)

Cost-effectiveness analysis of sofosbuvir plus ribavirin in patients with genotype 2 chronic hepatitis C: an analysis with real world outcomes from a multicentre cohort in Japan
por: Igarashi, Ataru, et al.
Publicado: (2019)

Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China
por: Gu, Lijun, et al.
Publicado: (2015)

Lamivudine treatment for severe acute HBV hepatitis
por: Lisotti, Andrea, et al.
Publicado: (2008)

Incidence of Hepatocellular Carcinoma after Treatment with Sofosbuvir-Based or Sofosbuvir-Free Regimens in Patients with Chronic Hepatitis C
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Development of Hepatocellular Carcinoma in Patients Aged 75–84 Years With Chronic Hepatitis C Treated With Direct-Acting Antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2020)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B: week 144 results from a real‐world, multi‐centre cohort study
por: Ogawa, Eiichi, et al.
Publicado: (2022)

Influence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C
por: Hayashi, Takeo, et al.
Publicado: (2016)

Molecular epidemical characteristics of Lamivudine resistance mutations of HBV in southern China
por: Li, Si-Yue, et al.
Publicado: (2011)

Long‐term assessment of recurrence of hepatocellular carcinoma in patients with chronic hepatitis C after viral cure by direct‐acting antivirals
por: Ogawa, Eiichi, et al.
Publicado: (2021)

Efficacy of tolvaptan for the patients with advanced hepatocellular carcinoma
por: Miyazaki, Masayuki, et al.
Publicado: (2017)

Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa
por: Stewart, Balint, et al.
Publicado: (2011)

Early dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNα2a shows earlier viral decline than peg-IFNα2b in combination therapy with ribavirin
por: Fujino, Tatsuya, et al.
Publicado: (2011)

HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review
por: Chen, Xiu-Li, et al.
Publicado: (2013)

Establishment and Characterization of Choroid Plexus Carcinoma Cell Lines: Connection between Choroid Plexus and Immune Systems
por: Enjoji, Munechika, et al.
Publicado: (1996)

Interferon-α-Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections
por: Shimoda, Shinji, et al.
Publicado: (2013)

A Novel Hydrodynamic Injection Mouse Model of HBV Genotype C for the Study of HBV Biology and the Anti-Viral Activity of Lamivudine
por: Li, Xiumei, et al.
Publicado: (2016)

Leptin attenuates D(2) receptor‐mediated inhibition of putative ventral tegmental area dopaminergic neurons
por: Murakami, Takami, et al.
Publicado: (2018)

The Effect of Prophylactic Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in Lymphoma Patients with High Baseline HBV DNA during Chemotherapy
por: Cai, Qingqing, et al.
Publicado: (2016)

Single-virion sequencing of lamivudine-treated HBV populations reveal population evolution dynamics and demographic history
por: Zhu, Yuan O., et al.
Publicado: (2017)

Fibrosis in nonalcoholic fatty liver disease: Noninvasive assessment using computed tomography volumetry
por: Fujita, Nobuhiro, et al.
Publicado: (2016)

Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand
por: Khamduang, Woottichai, et al.
Publicado: (2012)

Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy
por: Costantini, Andrea, et al.
Publicado: (2011)

Evaluation of adefovir & lamivudine in chronic hepatitis B: Correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis
por: Pradeep, Kumar S, et al.
Publicado: (2011)

Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine
por: Yasutake, Yoshiaki, et al.
Publicado: (2020)

Comparing Efficacy of Lamivudine, Adefovir Dipivoxil, Telbivudine, and Entecavir in Treating Nucleoside Analogues Naïve for HBeAg-Negative Hepatitis B with Medium Hepatitis B Virus (HBV) DNA Levels
por: Shi, Hong, et al.
Publicado: (2017)

Radiomics‐based classification models for HBV‐related cirrhotic patients with covert hepatic encephalopathy
por: Luo, Sha, et al.
Publicado: (2020)

Inhibition of nonhomologous end joining‐mediated DNA repair enhances anti‐HBV CRISPR therapy
por: Murai, Kazuhiro, et al.
Publicado: (2022)

Changing pleural fluid triglyceride levels in cirrhotic chylothorax
por: Chan, Ka Pang, et al.
Publicado: (2022)

Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine
por: Santos, Eneida A, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ncehih01i3mbalvispb0mdpd0f